STMicroelectronics announces status of common share repurchase program Disclosure of transactions in own shares – Period from September 29, 2025 to October 03, 2025 AMSTERDAM – October 06, 2025 -- STMicroelectronics N.V. (the “Company” or “STMicroelectronics”), a global semiconductor leader serving customers across the spectrum of electronics applications, announces full details of its common share repurchase program (the “Program”) disclosed via a press release dated June 21, 2024. The Program was approved ...

Brown-Forman Corporation (NYSE: BF.B ) initiated a share repurchase program. The spirit producer's growth outlook is increasingly weakened by secular trends, though, in my opinion, not making the program a very accretive use of capital. Brown-Forman's earnings will remain strong, butI am an avid investor with a major focus on small cap companies with experience in investing in US, Canadian, and European markets. My investment philosophy to generating great returns on the stock market revolves around identif ...

CORAL GABLES, Fla., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing and commercializing novel medicines for people living with rare and difficult-to-treat diseases, today announced that its Board of Directors has authorized a new share repurchase program to repurchase up to $200 million of shares of Catalyst's outstanding common stock between October 1, 2025, and Decemb ...

Oct 1, 2025 6:00 AM Eastern Daylight Time Share BOCA RATON, Fla.--(BUSINESS WIRE)--The GEO Group, Inc. (NYSE:GEO) ("GEO") will release its third quarter 2025 financial results on Thursday, November 6, 2025 before the market opens. GEO has scheduled a conference call and simultaneous webcast for 11:00 AM (Eastern Time) on Thursday, November 6, 2025. Hosting the call for GEO will be George Zoley, Executive Chairman of the Board, J. David Donahue, Chief Executive Officer, and Mark Suchinski, Chief Financial Of ...

WARSAW, N.Y., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Financial Institutions, Inc. (NASDAQ: FISI) (the “Company”), the parent company of Five Star Bank and Courier Capital, LLC, today announced that its Board of Directors (the “Board”) has approved a new share repurchase program for up to 1,006,379 shares of its common stock, or approximately 5% of the Company’s outstanding common shares. Effective September 18, 2025, the new share repurchase program replaces and terminates the prior share repurchase program aut ...

Core Insights - Curtiss-Wright Corporation (CW) announced a $200 million expansion in its 2025 share repurchase program, increasing total expected repurchases for the year to over $450 million, which may attract investors [1][9] - The company will execute this expansion immediately while continuing its ongoing $60 million buyback initiative launched in January 2025, leaving $134 million of authorized share repurchases remaining after both programs [2][9] Financial Performance - CW has secured a solid backlog worth $3.9 billion, with expectations to recognize approximately 90% as revenues over the next 36 months, supporting ongoing shareholder-friendly initiatives [6][9] - The company reported a year-over-year revenue growth of 11.7% in Q2 2025, driven by steady order inflows in high-priority categories such as defense and commercial aerospace [4][9] - CW's free cash flow totaled $117 million during the first half of 2025, which is 17% higher than the previous year, enabling further expansion of its share repurchase program [5][9] Market Position and Comparisons - The increasing demand for CW's defense products and the rising global defense budget are expected to translate into strong revenue growth, enhancing the company's financial strength and ability to reward shareholders [7] - Other defense companies, such as General Dynamics, Northrop Grumman, and Lockheed Martin, have also increased their share repurchase programs, indicating a trend within the industry to enhance shareholder value [8][10][11] Stock Performance - CW's stock has gained 62.3% over the past six months, significantly outperforming the industry average growth of 25.8% [12]

Financial Data and Key Metrics Changes - Q2 net sales grew by nearly 9% year over year to $3.1 billion, exceeding the high end of guidance range [5][17] - Gross margin reached 30.4%, expanding by nearly 90 basis points year over year [7][17] - Adjusted net income was $141.1 million, representing a 34.8% increase year-over-year [18] - Adjusted EBITDA was $183.3 million, with a margin of 5.9%, reflecting an 80 basis points year-over-year margin expansion [8][19] - Free cash flow for Q2 was nearly $106 million [8][19] Business Line Data and Key Metrics Changes - Autoship customer sales reached $2.58 billion, representing 83% of Q2 net sales and growing nearly 15% year over year [5][6] - Hardgoods business grew over 15% in Q2, driven by structural volume growth [6] - Active customers increased to 20.9 million, reflecting 4.5% year-over-year growth [7] Market Data and Key Metrics Changes - The overall industry is experiencing low to mid-single-digit growth, while Chewy is gaining market share [5][21] - NESPAC (Net Effective Sales Per Active Customer) reached $591, representing 4.6% year-over-year growth [7] Company Strategy and Development Direction - Chewy is focused on expanding its Chewy+ membership program and private brands, including the launch of a new fresh dog food line called Get Real [9][12] - The company plans to open 8 to 10 new Chewy Vet Care practices in fiscal year 2025 [9] - Chewy aims to mitigate tariff-related costs and invest in growth initiatives while maintaining a strong customer experience [15][22] Management's Comments on Operating Environment and Future Outlook - Management expects the second half of 2025 to be dynamic, with a focus on growth despite potential inflationary pressures [15] - The company anticipates continued share gains in the U.S. market and a strong long-term outlook [15][22] - Management remains optimistic about the performance of the Chewy+ program and its contribution to net sales [10][74] Other Important Information - The company repurchased approximately 3 million shares for about $125 million in Q2 [19] - Chewy ended the quarter with approximately $592 million in cash and cash equivalents, remaining debt-free [20] Q&A Session Summary Question: Can you talk more about the investments required in the back half and into 2026? - Management indicated that investments will focus on enhancing customer discoverability and increasing participation in Chewy+ without significant external marketing spend [26] Question: How should we think about the leverage path into the back half? - Management expects SG&A leverage to improve in the back half of the year, driven by the ramp-up of fulfillment centers and structural growth [34][39] Question: Can you unpack the Q2 gross margin improvement? - Management attributed gross margin expansion to product mix, increasing Autoship penetration, and a rational promotional environment [43] Question: What are your expectations regarding net household formations? - Management expects pet households to remain stable or slightly increase, with Chewy continuing to gain market share [61] Question: How is Chewy positioned against retail giants? - Management emphasized Chewy's unique value proposition, combining e-commerce efficiency with personalized service, allowing for continued market share growth [72][74] Question: Can you elaborate on the quality of cohorts improving year-over-year? - Management noted that improved customer engagement through programs like Autoship and Chewy+ is leading to higher NESPAC and retention rates [78]

Financial Data and Key Metrics Changes - Q2 net sales grew by nearly 9% year over year to $3.1 billion, exceeding the high end of guidance range [5][17] - Gross margin reached 30.4%, expanding by nearly 80 and 90 basis points sequentially and year-over-year, respectively [7][17] - Adjusted net income was $141.1 million, representing a 34.8% increase year over year, with adjusted diluted earnings per share of $0.33 [18][23] - Free cash flow for Q2 was nearly $106 million, with a robust liquidity position of approximately $1.4 billion [8][20] Business Line Data and Key Metrics Changes - Autoship customer sales reached $2.58 billion, representing 83% of Q2 net sales and growing nearly 15% year over year [5][6] - Hardgoods business grew over 15% in Q2, driven by structural volume growth [6] - Chewy Plus program showed strong growth, with approximately 3% of total monthly sales attributed to members [10][74] Market Data and Key Metrics Changes - Active customers increased to 20.9 million, reflecting 4.5% year-over-year growth [7] - NESPAC (Net Effective Sales Per Active Customer) reached $591, representing 4.6% year-over-year growth [7] - The overall pet industry is expected to grow in low single-digit to mid-single-digit range, while Chewy is growing at a rate of 7% to 8% [61][63] Company Strategy and Development Direction - Chewy is focusing on expanding its Chewy Vet Care network and plans to open 8 to 10 new practices in fiscal year 2025 [9] - The company is investing in its Chewy Plus membership program and private brands, including the launch of a new fresh dog food line called Get Real [11][12] - Chewy aims to mitigate tariff-related costs and enhance customer experience through strategic pricing and inventory management [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in Chewy's ability to gain market share and deliver strong growth despite macroeconomic pressures [15][22] - The company expects to maintain adjusted EBITDA margin expansion driven by improvements in gross margin [22] - Management anticipates continued growth in active customers and NESPAC, with a focus on enhancing customer engagement through programs like Autoship and Chewy Plus [63][78] Other Important Information - The company repurchased approximately 3 million shares for a total of approximately $125 million in Q2 [19] - Chewy remains debt-free with a strong cash position, allowing for continued investment in growth initiatives [20] Q&A Session Summary Question: Investments required in the back half and increasing awareness of new offerings - Management indicated that they are focusing on existing members for Chewy Plus and have not spent additional marketing dollars externally, relying on organic growth from existing customers [26] Question: SG&A deleverage and expectations for the back half - Management expects SG&A leverage to improve in the back half of the year, driven by the ramp-up of fulfillment centers and structural growth [34][39] Question: Drivers of gross margin expansion and advertising environment - Management highlighted that gross margin expansion is driven by product mix, increasing Autoship penetration, and a rational promotional environment [44][64] Question: Quality of customer cohorts and growth in Autoship - Management noted that the quality of cohorts is improving due to better retention in programs like Autoship and Chewy Plus, leading to higher NESPAC [78]

Company Overview - TG Therapeutics, Inc. has completed a $100 million share repurchase program, initially announced in August 2024, repurchasing approximately 3.5 million shares at an average price of $28.55 per share [1][3] - The Board of Directors has authorized a new share repurchase program for an additional $100 million of common stock, which may be executed through various means depending on market conditions [2] Financial Performance - In August 2025, the company repurchased about $78 million worth of stock, indicating a strategic move to enhance shareholder value [3] - The company believes that current market prices do not reflect the potential of its product BRIUMVI and its long-term growth prospects [3] Product Information - BRIUMVI (ublituximab-xiiy) is a novel monoclonal antibody targeting CD20-expressing B-cells, designed for efficient B-cell depletion at low doses [4] - It is indicated for the treatment of adults with relapsing forms of multiple sclerosis (RMS) in the U.S. and Europe, including various specific conditions [5][24] Market Position - TG Therapeutics is focused on the acquisition, development, and commercialization of treatments for B-cell diseases, with BRIUMVI being a key product approved by regulatory agencies in multiple regions [24]

Core Viewpoint - TerrAscend Corp. has authorized a renewal of its normal course issuer bid (NCIB) to repurchase up to USD $10 million of its common shares over a 12-month period, reflecting confidence in the company's value amid regulatory momentum in the cannabis sector [1][2]. Share Repurchase Program - The new NCIB allows for the repurchase of up to 10 million shares, representing 4.73% of the public float based on 306 million shares outstanding as of August 14, 2025 [3][4]. - The previous NCIB, which started on August 22, 2024, resulted in the repurchase of 1,279,400 shares for approximately $616,000 (CAD$855,000) at an average price of $0.47 (CAD$0.67) per share [2][4]. - The company is not obligated to repurchase shares and may suspend or terminate the program at its discretion if better uses for cash reserves are identified [3][4]. Market Context - The company operates in the North American cannabis sector, with interests in multiple states including Pennsylvania, New Jersey, Maryland, Ohio, Michigan, and California [5]. - TerrAscend's operations include cultivation, processing, and retail through brands such as The Apothecarium and Gage, providing a diverse product selection for both medical and adult-use markets [5]. Regulatory Environment - The cannabis industry in the United States is subject to significant legal restrictions, as cannabis remains a Schedule I drug under federal law, which poses risks to operations [6][7]. - Despite a trend toward non-enforcement of federal laws against compliant state programs, strict adherence to state laws does not absolve the company from federal liability [7].